GU Cancer

Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis

This poster reports DFS and OS outcomes in patients with high-risk MIBC who had persistent ctDNA− status post-cystectomy (through 12 months) using data from surveillance arm of the global, double-blind, randomized Phase III IMvigor011 study.

A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)

This poster describes the design of a global, open-label, randomised Phase II study evaluating tobemstomig with or without tiragolumab compared with atezolizumab in platinum-ineligible patients with previously untreated, locally advanced or mUC. The study rationale, eligibility criteria, endpoints and enrolment details are reported.

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)

This oral presentation reports clinical outcomes with neoadjuvant atezolizumab in patients with invasive non-conventional UC subtypes from the ABACUS-2 clinical study. Data presented include pCR (primary endpoint) and safety.

Early efficacy results from atezolizumab with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA)

AUREA poster description: This poster reports data from the phase II trial SOGUG-AUREA, evaluating first-line atezolizumab plus split-dose cisplatin in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for full doses of platinum-based chemotherapy. Early efficacy and safety data are presented.

Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): final OS from the randomized Ph III IMvigor130 study

Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study

External site

Genitourinary (GU) Cancer

Ask a question or share feedback